PRIMARY ENDPOINT: PFS BY INVESTIGATOR ASSESSMENT
62% maturity
(342 events in 556 patients at DCO): osimertinib: 136 events (49%), SoC: 206 events (74%)
Ramalingam, ESMO 2017